KALA BIO, Inc.
NASDAQ:KALA · NASDAQ Global Select
+$0.58 today
Vol 0.96M · Avg 0.08M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-385.6%
avg -232.0%
ROIC
-559.8%
avg -139.8%
ROA
-284.3%
avg -93.4%
Analysis
ROA is currently the strongest return metric at -284.3% versus its period average of -93.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Mary Reumuth | Treasurer & Secretary | $1.01M | — | 51 | $28,906.00 | 0.13% |
Vincent Kosewski | Senior Vice President of Manufacturing & Supply Chain Management | — | — | 63 | — | — |
Jill S. Steier | Executive Director of Investor Relations & Corporation Communications | — | — | — | $13,091.00 | 0.06% |
Francis S. Mah | Chief Medical Advisor | — | — | — | $13,091.00 | 0.06% |
Justin Hanes | Founder & Chair of the Scientific Advisory Board | — | — | — | $601,923.00 | 2.74% |
Avi Minkowitz | CEO, CFO & Director | — | — | 38 | $0.00 | <0.01% |
Carl Rennie | Executive Director of Account Management | — | — | — | — | — |
Patrick Bedell | Executive Director of Trade & Alternate Channels | — | — | — | — | — |
Josiah Craver | Senior Vice President & Corporate Controller | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
15
$1.43M
Net Sentiment
$1.43M
Net selling
Most Active
BAKER BROS. ADVISORS LP
4 transactions
1–10 of 15
Analysis
Insiders reported 0 buys worth $0.00 and 15 sells worth $1.43M over the last 12 months. That adds up to net selling of $1.43M. BAKER BROS. ADVISORS LP was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
VYNE Therapeutics Inc.
VYNE
$10.78M
Impact BioMedical Inc.
IBO
$7.07M
XTL Biopharmaceuticals Ltd.
XTLB
$5.84M
Soligenix, Inc.
SNGX
$4.16M
Pasithea Therapeutics Corp.
KTTA
$3.74M
Oragenics, Inc.
OGEN
$2.73M
Can-Fite BioPharma Ltd.
CANF
$2.62M
Ensysce Biosciences, Inc.
ENSC
$2.58M
AIM ImmunoTech Inc.
AIM
$1.26M
Abpro Corporation
ABP
$1.06M
Who manages KALA?
KALA BIO, Inc. (KALA) lists 9 active executives. The top listed executive is Vincent Kosewski, Senior Vice President of Manufacturing & Supply Chain Management.
Are KALA insiders buying or selling?
Recent insider activity shows net selling of $2.45M.
Explore More
Continue the stock analysis
Jump to another research area for this company.